282 related articles for article (PubMed ID: 36053302)
21. Gut Immunity and Microbiota Dysbiosis Are Associated with Altered Bile Acid Metabolism in LPS-Challenged Piglets.
Xiao X; Cheng Y; Fu J; Lu Z; Wang F; Jin M; Zong X; Wang Y
Oxid Med Cell Longev; 2021; 2021():6634821. PubMed ID: 33833852
[TBL] [Abstract][Full Text] [Related]
22. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?
Villard A; Boursier J; Andriantsitohaina R
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G485-G495. PubMed ID: 33471632
[TBL] [Abstract][Full Text] [Related]
23. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
24. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases.
Sharma SP; Suk KT; Kim DJ
World J Gastroenterol; 2021 Oct; 27(37):6161-6179. PubMed ID: 34712025
[TBL] [Abstract][Full Text] [Related]
25. Potential mechanisms linking gut microbiota and portal hypertension.
Baffy G
Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
[TBL] [Abstract][Full Text] [Related]
26. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
Wang T; Ishikawa T; Sasaki M; Chiba T
Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
[TBL] [Abstract][Full Text] [Related]
27. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
28. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut.
Ridlon JM; Kang DJ; Hylemon PB; Bajaj JS
Dig Dis; 2015; 33(3):338-45. PubMed ID: 26045267
[TBL] [Abstract][Full Text] [Related]
29. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases.
Bruneau A; Hundertmark J; Guillot A; Tacke F
Front Med (Lausanne); 2021; 8():725390. PubMed ID: 34650994
[TBL] [Abstract][Full Text] [Related]
30. The role of microbiota in nonalcoholic fatty liver disease.
Di Ciaula A; Bonfrate L; Portincasa P
Eur J Clin Invest; 2022 Jul; 52(7):e13768. PubMed ID: 35294774
[TBL] [Abstract][Full Text] [Related]
31. Role of Intestinal Microbes in Chronic Liver Diseases.
Xu M; Luo K; Li J; Li Y; Zhang Y; Yuan Z; Xu Q; Wu X
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293518
[TBL] [Abstract][Full Text] [Related]
32. Gut Microbiota and Complications of Liver Disease.
Acharya C; Bajaj JS
Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
[TBL] [Abstract][Full Text] [Related]
33. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.
Petrov PD; García-Mediavilla MV; Guzmán C; Porras D; Nistal E; Martínez-Flórez S; Castell JV; González-Gallego J; Sánchez-Campos S; Jover R
Mol Nutr Food Res; 2019 Oct; 63(20):e1900487. PubMed ID: 31322321
[TBL] [Abstract][Full Text] [Related]
34. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.
Park JW; Kim SE; Lee NY; Kim JH; Jung JH; Jang MK; Park SH; Lee MS; Kim DJ; Kim HS; Suk KT
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008852
[TBL] [Abstract][Full Text] [Related]
35. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
[TBL] [Abstract][Full Text] [Related]
36. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
37. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
Rizzetto L; Fava F; Tuohy KM; Selmi C
J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
[TBL] [Abstract][Full Text] [Related]
38. Interplay between Dysbiosis of Gut Microbiome, Lipid Metabolism, and Tumorigenesis: Can Gut Dysbiosis Stand as a Prognostic Marker in Cancer?
Chattopadhyay I; Gundamaraju R; Jha NK; Gupta PK; Dey A; Mandal CC; Ford BM
Dis Markers; 2022; 2022():2941248. PubMed ID: 35178126
[TBL] [Abstract][Full Text] [Related]
39. The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases.
Fogelson KA; Dorrestein PC; Zarrinpar A; Knight R
Gastroenterology; 2023 Jun; 164(7):1069-1085. PubMed ID: 36841488
[TBL] [Abstract][Full Text] [Related]
40. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho MS; Kim SY; Suk KT; Kim BY
J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
